Abstract:OBJECTIVE To evaluate the efficacy of cyclosporin A (CyA) therapy in 83 children with nephrotic syndrome of different pathological types. METHODS Eighty-three children enrolled in this study were all hospitalized children with idiopathic nephrotic syndrome, aged 3 to 14 yrs (average 8.3 yrs) and included 52 males and 31 females. There were 35 cases with steroid-dependent, 17 with steroid resistant and 26 with frequent relapses. CyA was given to each patient with dosage of 5 mg/(kg.d) during the corticosteroid was diminished. The renwal biopsy was performed in all patients before the administration of CyA. The duration of CyA therapy lasted for about 3 to 6 months. The plasma concentration of CyA was monitored. RESULTS Eighty-three children with nephrotic syndrome of different pathological types were treated with CyA, including 42 cases of minimal change nephrotic syndrome (MCNS), 31 cases of mesangioproliferative glomerulonephritis (MsPGN), 5 cases of membranoproliferative glomerulonephritis (MPGN) and 4 cases of focal segmental glomerular sclerosis (FSGS). All the 83 patients tolerated well to the CyA treatment. Forty-five cases got complete remission, 23 partial remission, 15 cases no change after one month treatment with CyA in the hospital. The overall response rate was 82%. Patients with different renal pathological types showed different responses. Among them, MCNS and MsPGN exhibited the best response rates of 86% and 84%, respectively; MPGN cases showed a lower response rate and FSGS cases showed the lowest rate. The response time was 7 to 45 days. The blood concentration of CyA was monitored for 1 week and 2 weeks after the drug was given. The effective drug concentration was maintained at 100 to 200 microg/L, and the course lasted for 3 to 6 months. During the follow-up of 83 cases, in 17 of 68 cases the disease relapsed when therapy was tapered or discontinued. The relapse rate was 25%. The results indicated that CyA would be effective to the relapsed cases. The serum creatinine increased temporarily after administration of CyA in 5 cases, N-acetyl-beta-D-glucosaminidase (NAG) in 8 cases and eventually reached the normal range after the adjustment of dosage. The side effects included anorexia, nausea, vomiting and so on. CONCLUSION CyA is one of the effective substitutes for the treatment of nephrotic syndrome, especially for the cases with MCNS and MsPGN. And CyA could control refractory nephrotic syndrome effectively and rapidly. The clinical effect was related to the blood concentration of CyA and pathological types.

CYCLOSPORINE A TREATMENT IN PATIENTS WITH MEMBRANOUS LUPUS NEPHROPATHY

Cyclosporine A in Treatment of Membranous Lupus Nephropathy

Combined Immunosuppressive Treatment (CIST) in Lupus Nephritis: a Multicenter, Randomized Controlled Study.

Low-dose Cyclosporine in Treatment of Membranous Nephropathy with Nephrotic Syndrome: Effectiveness and Renal Safety

Cyclosporin A Treatment for Idiopathic Membranous Nephropathy.

Tacrolimus versus cyclophosphamide as treatment for diffuse proliferative or membranous lupus nephritis: a non-randomized prospective cohort study.

Preliminary observation of low-dose cyclosporine A combined with low-dose prednisone in the treatment of patients with idiopathic membranous nephropathy

Low-Dose Cyclosporine Treatment in Chinese Nephrotic Patients with Idiopathic Membranous Nephropathy: an Uncontrolled Study with Prospective Follow-Up

[Cyclosporin A Treatment of 83 Children with Nephrotic Syndrome of Different Pathological Types].

Long-term Effects of Cyclosporine A in Children with Steroid-Resistant Idiopathic Nephrotic Syndrome and Outcomes of the Patients

Early Initiation of Tacrolimus or Cyclophosphamide Therapy for Idiopathic Membranous Nephropathy with Severe Proteinuria.

Effect of cyclophosphamide combined with glucocorticoid therapy on idiopathic membranous nephropathy: A multicenter open-label randomized controlled trial

Tacrolimus Combined with Corticosteroids in Treatment of Nephrotic Idiopathic Membranous Nephropathy: A Multicenter Randomized Controlled Trial

Treatment of Myelodysplastic Syndrome with Cyclosporin A

The Efficacy and Safety of Tacrolimus Monotherapy in Adult-Onset Nephrotic Syndrome Caused by Idiopathic Membranous Nephropathy

Combination Therapy of Prednisone and Cyclophosphamide for Patients with Idiopathic Membranous Nephropathy:A Prospective Randomized Controlled Trial

Reduced-Dose Cyclosporine with Mycophenolate Mofetil and Prednisone Significantly Improves the Long-Term Glomerular Filtration Rate and Graft Survival

[Curative Effects of Cyclosporin A Therapy Upon Myelodysplastic Syndrome].

Tacrolimus As a Steroid-Sparing Agent for Adults with Steroid-Dependent Minimal Change Nephrotic Syndrome

Tacrolimus therapy in adults with steroid- and cyclophosphamide-resistant nephrotic syndrome and normal or mildly reduced GFR.

Effects of Cyclosporine A on Serum and Urinary Soluble Interleukin-2 Receptor in Patients with Lupus Nephritis.